Inside PIC/S: Top GMP Deficiencies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Top GMP Deficiencies
Comparison of the top GMP deficiencies cited by the PIC/S Participating Authorities.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 135-137

Results

Thirty-three out of 39 PIC/S Participating Authorities responded (85%). Seven out of 9 applicants to PIC/S responded (78%). The top most frequently cited categories of GMP deficiencies were:

  • Documentation—manufacturing (24)
  • Design and maintenance of premises (22)
  • Documentation—quality systems (elements / procedures) (20)
  • Personnel issues—training (19)
  • Design and maintenance of equipment (18)
  • Cleaning validation (14)
  • Process validation (14)
  • Product quality review (14)
  • Supplier and contractor audit (13)
  • Calibration of measuring and test equipment(12)
  • Equipment validation (11).

The total number of deficiencies per group of top 10 most frequently cited deficiencies were:

  • Production (99, or 24%)
  • Quality system (82, or 20%)
  • Quality control (59, or 14%)
  • Premises and equipment (58, or 14%)
  • Validation (52, or 12%)
  • Personnel issues (34, or 8%)
  • Materials management (29, or 7%)
  • Regulatory issues (5, or 1%)


Figure 1: Most severe cited GMP deficiencies.
The top most severe GMP deficiencies were (see Figure 1):
  • Design and maintenance of premises (15)
  • Contamination, potential for (chemical, physical, microbial) (12)
  • Design and maintenance of equipment (11)
  • Sterility assurance (9)
  • Batch-release procedures (9)
  • Process validation (9)
  • Cleaning validation (8)
  • Investigation of anomalies (7)
  • Documentation—quality systems (elements/procedures) (7)
  • Regulatory issues—noncompliance with marketing authorization (5)
  • Documentation—manufacturing (5).


Figure 2: Top most severe deficiencies by group.
The total number of deficiencies per group of the top most severe deficiencies were (see Figure 2):
  • Production (44, or 27%)
  • Quality system (32, or 20%)
  • Premises and equipment (28, or 17%)
  • Validation (22, or 14%)
  • Quality control (14, or 9%)
  • Regulatory issues (9, or 6%)
  • Materials management (8, or 5%)
  • Personnel issues (5 or 3%).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here